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Abstract
Rationale—Tobacco use is a serious health problem in the United States and this problem is 
potentiated in patients with schizophrenia. The reward system is implicated in schizophrenia and 
may contribute to the high comorbidity between nicotine use and schizophrenia but very little 
research has been done on the topic. The reward-enhancement effect of nicotine has been shown to 
be important in nicotine use, but there have been no studies on this effect in animal models of 
schizophrenia.
Objectives—This study was designed to determine the effects of phencyclidine, used to model 
negative symptoms of schizophrenia, on self-administration of nicotine with or without a co-
occurring sensory reinforcer [i.e., visual stimulus (VS)] in rats.
Methods—Phencyclidine (2.0 mg/kg) was administered before each of 7 nicotine self-
administration sessions (0.01 mg/kg/inf) after which rats (n=8–9 per group) were given 7 days of 
extinction without phencyclidine pretreatment. Reinstatement using phencyclidine (2.0 mg/kg), 
nicotine (0.2 mg/kg), and yohimbine (1.25 mg/kg, a pharmacological stressor) were tested after 
extinction to determine if previous exposure to phencyclidine would alter reinstatement of active 
lever pressing.
Results—Phencyclidine initially decreased nicotine self-administration, but only in the groups 
with a concurrent VS. This decrease in self-administration dissipated after 5 days. During 
reinstatement, rats that had previously received phencyclidine during self-administration with a 
VS were more sensitive to stress-induced reinstatement than any other group.
Conclusions—These results show a transitory effect of phencyclidine on nicotine self-
administration. Phencyclidine may induce a potential sensitivity to pharmacological stressors 
contributing to reinstatement of nicotine.
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Introduction
Tobacco use is a serious problem in the United States; more than 480,000 people die each 
year from nicotine-related health concerns (Center for Disease Control 2014). 
Schizophrenics use tobacco at a much higher rate than the general population, with 50–90% 
of schizophrenics using nicotine (the primary psychoactive component in tobacco) in some 
form compared to around 22% of non-mentally ill people (Kumari & Postma 2005). The 
high rate of smoking and nicotine use in schizophrenia patients leads to an increased 
incidence of cardiovascular and respiratory problems that contributes to a mortality rate 
attributed to smoking that is 2 to 3 times higher than the general population (Hennekens et 
al. 2005; Parks et al. 2006; Saha et al. 2007; Mortenson & Juel 1990; Buda et al 1988). 
Nicotine addiction is exceedingly detrimental to patients with schizophrenia and potential 
mechanisms behind this comorbidity need to be explored.
While the comorbidity between nicotine use and schizophrenia is well documented, there is 
no consensus as to the mechanisms contributing to this comorbidity. The brain reward 
system has been implicated in nicotine addiction (Merlo-Pich et al. 1997; Koob & LeMoal 
2006) and in schizophrenia (AhnAllen et al. 2012; Der-Avakian & Markou 2012; Wolf 
2006; Kring & Moran 2008; Ziauddeen & Murray 2010). Given that this system is involved 
in both pathologies, the lack of research on the role of the dopaminergic reward system in 
this comorbidity is surprising. The few studies done on reward dysregulation in both 
schizophrenia and nicotine show a potential connection between the two. In humans, high 
levels of nicotine dependence are correlated with the severity of anhedonia, one of the 
primary negative symptoms of schizophrenia (AhnAllen et al. 2012). In another clinical 
report, patients with schizophrenia rated smoking as more rewarding than other reinforcers 
(Smith et al. 2002). Finally, the subcortical reward system and prefrontal cortex are 
hypofunctional in schizophrenics (Watkins et al., 2000; Chambers et al., 2001), suggesting 
involvement of the reward circuitry in the high rates of smoking seen in patients with 
schizophrenia.
One factor indicated in nicotine addiction is the reward or reinforcer-enhancement effect of 
nicotine. The reward-enhancement effect is defined as a potentiation by nicotine of the 
reinforcing effects of other non-nicotine stimuli. This enhancement effect has been seen as 
an increase in operant responding maintained by reinforcers such as auditory and visual 
cues, food, water, and social interaction (Liu et al. 2007; Donny et al. 2003; Chaudhri et al. 
2007; Palmatier et al. 2006; Palmatier et al. 2007; Caggiula et al. 2009; Raiff & Dallery 
2006; Raiff & Dallery 2008; Raiff & Dallery 2009; Thiel et al. 2009; Barrett & Odum 
2011). Notably, some investigators suggest that the relatively robust reward-enhancement 
effects of nicotine may be more potent and hence more important for nicotine dependence 
than the relatively weaker primary reinforcing effects (Donny et al. 2003; Caggiula et al. 
2009). In fact, self-administration of nicotine has been consistently difficult to find in 
rodents, being influenced by a number of factors such as feeding regimen (Lang et al., 1977; 
Cox et al., 1984). When self-administration has been identified, responding maintained by 
nicotine is relatively low in comparison to other drugs of abuse (Risner & Goldberg 1983). 
Alternatively, when a cue such as a visual stimulus is coupled to the infusion of nicotine, 
rats have significantly heightened levels of nicotine self-administration (Caggiula et al. 
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2002). This evidence suggests that this heightened self-administration reflects the reward-
enhancement effect of nicotine increasing responding maintained by the weak sensory 
reinforcing effects of the visual stimulus (Caggiula et al. 2009; Caggiula et al. 2002).
To date, only one study to our knowledge has investigated nicotine use in a preclinical 
model of specific aspects of schizophrenia (Berg et al. 2013), which is surprising given that 
nicotine is used by patients with schizophrenia more than any other drug of abuse (Dolan et 
al. 2004). Berg and colleagues using the neonatal ventral hippocampal model found 
increased nicotine self-administration, leading to greater intake of nicotine, and later drug-
seeking behaviors (see Discussion). The present study will extend Berg’s work in three 
important ways. First, this study will utilize phencyclidine to model the negative symptoms 
of schizophrenia, examining the generalizability of findings between this model and the 
neonatal ventral hippocampal model used by Berg and colleagues (2013). Given the inherent 
behavioral differences seen between varying animal models of schizophrenia symptoms (see 
Jones et al. 2011 for review), exploring the potential similarities and differences between 
these two paradigms will inform research on preclinical modeling of aspects of 
schizophrenia. Second, this study will explicitly compare the reward-enhancement effect of 
nicotine and the primary reinforcing effect of nicotine by utilizing controls based on the 
seminal study by Caggiula and colleagues (2002). Finally, this study will examine 
potentially altered reinstatement to a cue (i.e. phencyclidine), a nicotine prime, and a 
pharmacological stressor (i.e. yohimbine) thereby providing an opportunity to identify other 
processes involved in the comorbidity between tobacco addiction and negative symptoms of 
schizophrenia.
Methods
Animals
Thirty-eight adult male Sprague Dawley rats (275–299 g upon arrival) from Harlan, 
(Indianapolis, IN) completed the study and were included in the final analyses. They were 
housed individually in clear rectangular polycarbonate tubs (48.3 × 26.7 × 20.3 cm) under 
12-hr light/dark conditions (light on at 6:00 am). Experiments were conducted during the 
light cycle. Room temperature was maintained at 22±1°C with a relative humidity of 45–
60%. Water was continuously available and food was available ad libitum until the 
beginning of the experiment in which rats were food-restricted to 90% of their free-feeding 
weight except for the day prior to surgery and 5 days following surgery in which food was 
available ad libitum. After four weeks, the target weight was increased by 2 g. Rats were 
allowed 5 days of habituation to the animal facility before the start of the experiment. 
During acclimation they were handled for 5 min per rat by each experimenter. All 
procedures were approved by the Institutional Animal Care and Use Committee at the 
University of Nebraska-Lincoln.
Drugs
(−)Nicotine tartrate salt (Sigma, St. Louis, MO) was dissolved in 0.9% saline and adjusted to 
a pH of 7.0 ± 0.2 with a dilute NaOH solution. Phencyclidine hydrochloride (PCP, a gift 
from NIDA Chemical Synthesis and Drug Supply Program [RTI, Research Triangle Park, 
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NC]) and yohimbine (Sigma) were dissolved in 0.9% saline. Saline and PCP (2.0 mg/kg) 
were administered subcutaneously (SC) 10 min prior to placement in the chamber. The dose 
and injection-to-placement interval of PCP was based on unpublished data suggesting that 
this dose would not produce a significant change in motor activity. This dose has also been 
used to model negative symptoms of schizophrenia in other studies. The overall paradigm 
used here is unique and aspects of the dosage and regimens were adopted from multiple 
studies (Sams-Dodd, 1997; Sams-Dodd, 1998; Corbett et al., 1995; Pouzet et al., 2002; 
Abdul-Monim et al. 2007; Abdul-Monim et al. 2003; Idris et al. 2005; Sams-Dodd, 1991). 
Yohimbine (1.25 mg/kg) was administered intraperitoneally (IP) 30 min prior to placement. 
The dose of yohimbine was chosen based on previous findings showing that reinstatement of 
drug-seeking was reliably seen after administration of 1.25 mg/kg (Shepard et al. 2004). The 
nicotine dose (0.01 mg/kg/infusion, reported as base) was selected based on previous 
research in our lab (Charntikov et al. 2013). Nicotine was infused intravenously (IV) at 
35.74 μl per infusion across 1 sec. On the nicotine reinstatement day, nicotine (0.2 mg/kg) 
was injected SC 5 min prior to placement in the chamber.
Self-Administration Chambers
Sessions were conducted in eight chambers (ENV-008CT; Med Associates, Inc., St. Albans, 
VT; measuring 30.5 × 24.1 × 21.0 cm, l x w x h) enclosed in light and sound-attenuating 
cubicles fitted with a fan. The sidewalls of the chambers were aluminum, while the ceiling 
and front and back walls were clear polycarbonate. One sidewall featured a dipper 
receptacle centered in the chamber, occupying a 5.2 × 5.2 × 3.8 cm (l × w × h) recessed 
space, into which a dipper arm when raised provided 0.1 ml of 26% sucrose solution (w/v) 
into the receptacle. Retractable metal levers (147 nN required for micro-switch closure) 
were featured on either side of the dipper receptacle, approximately 5 cm above the chamber 
floor. An infrared emitter/detector unit positioned 4 cm above the rod floor bisected the 
chamber 14.5 cm from the sidewall featuring the dipper receptacle. This unit monitored 
general locomotor activity during experimental sessions. White 28V DC lamps (2.54 cm 
diameter, 100 mA) were located 3 cm above each lever; termed the right and left cue lights. 
Two external 28V DC lamps (100 mA) were also located outside and above the chamber but 
within the sound attenuating cubicle; termed the houselight. The infusion pump 
(PMH-100VS; Med Associates, Inc.; St. Albans, VT) for each chamber was located outside 
the cubicle. A 5-ml syringe mounted on the infusion pump was connected with Tygon® 
tubing (AAQ04103; VWR; West Chester, PA, USA). The tubing was attached to a swivel 
coupled with a spring leash (C313C; Plastics One; Roanoke, VA, USA) which were 
suspended over the ceiling of the chamber on a balanced metal arm. A computer running 
Med Associates interface and software (MedPC for Windows, IV) started the experimental 
sessions and collected number of chamber beam breaks, infusions, and lever presses.
Surgical Procedures
Rats were anesthetized with 1 ml/kg ketamine (100 mg/ml)/xylazine (20 mg/ml) mixture at a 
2:1 ratio (IM; Sigma, St. Louis, MO). A polyurethane catheter (RJVR-23; Strategic 
Applications Inc.; Lake Villa, IL, USA) with rounded tip and double suture beads was 
implanted into the right external jugular vein. The other end of the catheter was placed 
subcutaneously around the shoulder and exited below the scapula via a polycarbonate back-
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mount access port (313-000BM; Plastics One Inc.; Roanoke, VA, USA). Catheters were 
immediately flushed with 0.2 ml of streptokinase (2 mg/ml; Sigma) after surgery diluted in 
sterile heparinized saline (30 U/ml; Midwest Veterinary Supply; Des Moines, IA, USA). 
Atipamezole hydrochloride (0.5 mg/kg; IM; Sigma) diluted in saline was used to counteract 
the anesthesia after the surgery was completed (Wee et al. 2006). Buprenorphine 
hydrochloride (0.1 mg/kg; SC; Sigma) was administered immediately after the surgery and 
once a day for two days post-surgery for pain management. Catheters were flushed before 
each self-administration session with heparinized saline (30 U/ml) and after each self-
administration session with the heparinized saline mixed with cefazolin (50 mg/ml, Midwest 
Veterinary Supply). Catheter patency was assessed after the seven days of self-
administration with an infusion of 0.05 ml xylazine (20 mg/ml; IV). This xylazine 
concentration produces motor ataxia within 5 sec (cf. Bevins 2005; Reichel et al. 2008). If 
rats failed to exhibit motor ataxia within 5 sec, they were excluded from the analyses and 
were not included in the subjects. Four animals were excluded from the study for this 
reason.
Procedure
Autoshaping
All rats were first trained in four consecutive autoshaping sessions. During these sessions, 
the house light remained on and a randomly selected lever was inserted into the chamber. A 
lever-press or a lapse of 15 sec resulted in sucrose delivery (4 sec), retraction of the lever, 
and a 20-sec timeout. Following the timeout, a randomly selected lever was inserted into the 
chamber with the condition that the same lever was not presented more than twice in a row. 
The session ended after 60 sucrose deliveries (total time of the session ranging from 65–80 
min). All rats reached the criterion of at least 80% of sucrose deliveries received by lever-
pressing by the final day of training.
Surgery and Post-surgery Autoshaping
Autoshaping was followed by the surgeries (see surgical procedures) and five days of rest, 
in which catheters were flushed daily but no testing was performed. After this recovery 
period, rats underwent three more days of autoshaping as described earlier. Prior to the first 
day of self-administration, rats had daily nicotine pre-injections (0.4 mg/kg, subcutaneous, 1 
h post-autoshaping sessions) to decrease the initial locomotor suppression effects of nicotine 
(Bevins et al. 2001). All rats were above the lever-pressing criterion by the final day of 
autoshaping. Rats were then pseudo-randomly assigned to one of four groups with the 
condition that the last 2 days of lever-pressing performance did not differ statistically. The 
groups were based on the drug received prior to each self-administration session (saline or 
PCP) and whether the visual stimulus (VS) was presented with the nicotine infusion 
resulting in the following four groups: SAL-NOVS, SAL-VS, PCP-NOVS, PCP-VS.
Self-Administration
Following 24 h after the last autoshaping session, there were 7 consecutive days of nicotine 
self-administration. Rats were injected with either saline or PCP (2 mg/kg) 10 min prior to 
chamber placement and then permitted to self-administer nicotine with or without the visual 
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stimulus. Before the start of each session, catheters were flushed with 0.2 ml of heparinized 
saline. The start of each 60-min session was signaled by turning the house light on, priming 
the catheter with nicotine (ca. 31 μl or 90% of total internal catheter volume), and insertion 
of both levers. The active lever was randomly assigned for each rat and was reinforced on a 
fixed ratio (FR) 1 schedule of reinforcement. If a rat pressed on the active lever once, there 
was a 1-sec infusion of nicotine (0.01 mg/kg/infusion) and termination of the house light for 
20 sec as a timeout period for all groups; no additional nicotine infusions were available 
during this timeout. In addition, there was illumination of the cue lights for the first 5 sec in 
the PCP-VS and SAL-VS groups. Pressing on the inactive lever had no programmed 
consequence.
Extinction/Reinstatement
After self-administration, all animals underwent seven days of extinction. During extinction, 
the session was similar but rats were not injected with any drug before the session and lever-
pressing on the active lever did not result in a nicotine infusion. However, cue lights were 
illuminated in the groups that previously received cue lights in the self-administration phase. 
Extinction lasted for 7 days. Finally, all rats underwent three tests to determine if 
reinstatement varied with treatment during the self-administration phase. On the first 
reinstatement test, all rats were injected with PCP (2 mg/kg, SC, 10 min prior to testing). 
The second reinstatement test examined nicotine (0.2 mg/kg, SC, 5 min); the final 
reinstatement test assessed yohimbine (1.25 mg/kg, IP, 30 min). The phencyclidine 
reinstatement test was performed first in order to most closely mimic the seven-day-on, 
seven-day-off phencyclidine regimen employed by a number of studies to mimic negative 
and cognitive symptoms of schizophrenia (Idris et al., 2005; McLean et al., 2009; Sams-
Dodd, 1991; Grayson et al., 2007; Cochran et al., 2003; Abdul-Monim et al. 2007; Abdul-
Monim et al. 2003; Bruins-Slot et al., 2005). Given the complete lack of knowledge on how 
yohimbine would interact with previous phencyclidine exposure, the yohimbine 
reinstatement test was performed last to prevent any carryover effects.
Statistics
All data are expressed as mean ± SEM. Data from the 7 self-administration days were 
analyzed using planned comparisons examining specific group differences to address the 
specific hypotheses of the study in a targeted fashion. Data from the reinstatement sessions 
were analyzed using a two-way ANOVA. A conventional alpha value of 0.05 was used to 
determine significance. Additionally, means and standard errors (SEM) are given while 
discussing specific differences. The discrimination index was calculated by dividing the 
total active lever presses by the total number of overall lever presses (both active and 
inactive). All data were analyzed using SPSS version 21.
Results
Self-Administration
Infusions—Total infusions of nicotine are shown in Figure 1. To examine the importance 
of the sensory reinforcer in general, a two-way mixed measures ANOVA with Group (SAL-
VS; SAL-NOVS) as a between-subjects factor and Session as a within subjects factor was 
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utilized. There was no main effect of Session (p=0.089), but there was a main effect of 
Group [F(1,16)=32.447, p<0.001], with the SAL-VS condition having more infusions that 
the SAL-NOVS condition (38.8±0.7 vs. 19.5±3.0). There was also a significant Session by 
Group interaction [F(6,96)=3.323, p=0.005]. This interaction was driven by the decreasing 
number of infusions in the SAL-NOVS conditions (24.5±4.7 to 8.9±2.2), but no difference 
in the SAL-VS condition. These findings indicate that nicotine self-administration was 
significantly increased by the presence of a VS coupled with the infusion.
To examine the hypothesis that PCP alters reward-enhancement by nicotine, a separate two-
way mixed measures ANOVA was conducted comparing the SAL-VS and PCP-VS groups 
with an additional factor of session. There was no main effect of Session and no interaction 
(ps≥0.12), but the main effect of Group approached criterion for significance 
[F(1,18)=3.848, p=0.065]. Further examination of the data pattern using planned one-way 
ANOVAs on the seven individual self-administration revealed a main effect of Group on the 
third [F(1,18)=7.259, p=0.015], fourth [F(1,18)=5.981, p=0.025] and fifth day 
[F(1,18)=0.013, p=0.013], but no effect on days 1, 2, 6, and 7 (ps≥0.176). These findings 
show that PCP altered the reward-enhancement effect of nicotine but this effect was 
somewhat transient.
Finally, a third two-way mixed measures ANOVA was conducted to determine if PCP 
changed nicotine self-administration that does not involve enhancement of a sensory 
reinforcer. The SAL-NOVS and PCP-NOVS groups were compared over daily sessions. 
There was a main effect of Session [F(6,96)=20.324, p<0.001], with infusions decreasing 
over days (29.42±3.6 to 20.6±3.9). There was no main effect of Group or interaction 
(ps≥0.23). This pattern indicates that self-administration decreased across session and that 
this decrease was not affected significantly by PCP.
Discrimination Index—Figure 2 shows the measure of the discrimination between the 
active and inactive lever for each group. A value of 0.5 indicates similar responding on the 
active and inactive lever; a value greater than 0.5 denotes more responding on the active 
(nicotine) lever. When comparing the SAL-NOVS and SAL-VS groups, there was a 
marginal main effect of Session [F(6,96)=2.197, p=0.050], a main effect of Group 
[F(1,16)=16.085, p=0.001] but no significant Session by Group interaction (p=0.55). These 
findings indicate that the discrimination index is higher in animals with a VS coupled to the 
infusion and this index increased over days (0.48±0.03 to 0.54±0.04), irrespective of groups. 
When comparing the SAL-VS groups and PCP-VS groups, there was a main effect of 
Session [F(6,96)=5.466, p<0.001] but no main effect of Group and no interaction (ps≥0.36), 
suggesting that PCP did not affect the discrimination index when a VS was coupled to the 
infusion but the discrimination index increased over days (0.57±0.03 to 0.78±0.04). Finally, 
when comparing the SAL-NOVS and PCP-NOVS groups, there were no main effects and no 
interactions (ps≥0.21). Together, this data indicates that the presence of a VS coupled with 
an infusion increased the discrimination index which also increased over days of self-
administration but this was not affected by administration of PCP.
Activity—Chamber activity for each group is shown in Figure 3. When comparing the 
SAL-NOVS and SAL-VS groups, there was a main effect of Session [F(6,96)=3.336, 
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p=0.005], a main effect of Group [F(1,16)=4.952, p=0.041] and a significant Session by 
Group interaction [F(6,96)=2.379, p=0.035]. These findings show that activity was higher in 
animals with a VS paired with the infusion and this increased over days (436.6±57 to 
503.7±58.5). The increase was primarily due to the activity increase in the SAL-VS group 
(517.5±98.9 to 668.4±74.3). When comparing the SAL-VS groups and PCP-VS groups, 
there was a main effect of Session [F(6,96)=2.196, p=0.049] with activity increasing over 
days (583.0±59.0 to 663.6±77.0). There was also a main effect of Group [F(1, 16)=5.676, 
p=0.28], with activity being higher in the PCP-VS group and an interaction [F(6,96)=3.504, 
p=0.003], with the session effect being driven by the SAL-VS group, which showed an 
increase in activity over days (517.5±98.9 to 668.4±74.3). Finally, when comparing the 
SAL-NOVS and PCP-NOVS groups, there was a main effect of Group [F(1,160=10.695, 
p=0.004], but no effect of Session and no interaction (ps≥0.22), suggesting that PCP 
increased activity even in the NOVS condition, but this did not change over session in 
comparison to SAL-NOVS. Overall, PCP increased activity over days in the VS groups and 
increased activity overall in the NOVS groups and the presence of a VS increased activity 
even with no PCP exposure.
Extinction
Findings from the extinction and reinstatement phases are shown in Figure 4. When 
comparing the SAL-NOVS and SAL-VS groups, there was a main effect of Group 
[F(1,16)=8.280, p=0.10] but no main effect of Session and no interaction (ps≥0.19), showing 
that there were higher levels of lever-pressing in extinction for the VS groups, but this did 
not change over time. There were no main effects and no interaction when comparing the 
SAL-NOVS and PCP-NOVS groups (ps≥0.33). When comparing the SAL-VS and PCP-VS 
groups, there was no main effect of Group (p=0.14), but there was an effect of Session 
[F(6,96)=2.983, p=0.010] and a marginally significant interaction [F(6,96)=2.184, p=0.050]. 
These results suggest that lever-pressing increased over extinction days in the VS groups 
(20.9±3.4 to 34.6±5.0) and this increase was specifically in the PCP-VS groups (16.7±3.9 to 
39.3±7.7).
Examining Figure 4, there was a clear drop in lever-pressing after nicotine was removed in 
the VS groups, providing strong support for the reward-enhancement effect of nicotine. The 
SAL-NOVS and PCP-NOVS groups had low levels of lever-pressing during self-
administration and thus had a low percentage drop after removal of nicotine (a 9% and a 5% 
decrease respectively). The SAL-VS and PCP-VS groups had a 57% and a 74% decrease in 
lever-pressing from self-administration to the first day of extinction, respectively. However, 
lever-pressing was higher in groups with the concurrent VS during extinction than in the 
NO-VS groups suggesting that the VS alone maintained a low level of lever-pressing. This 
finding supports the idea that the VS is a weak sensory reinforcer.
Reinstatement
PCP Reinstatement—There was a main effect of VS on the phencyclidine reinstatement 
day [F(1,34)=48.07, p<0.001], with rats in the VS group having higher active lever-pressing 
than the NO-VS groups. There was a main effect of PCP [F(1,34)=21.827, p<0.001], with 
rats having higher active lever-pressing if they were previously exposed to PCP. In addition, 
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there was an interaction of PCP and VS [F(1,34)=18.07, p<0.001]. Using LSD tests, rats in 
the PCP/VS groups had higher active lever-pressing than all other groups (LSDmmd=22.18). 
Active lever-pressing differed between the final extinction day and the PCP reinstatement 
test [F(1,34)=15.04, p<0.001] and this effect was specific to the PCP-VS group (p<0.001) as 
no other groups showed increased responding on the PCP reinstatement day (ps>0.05).
Examining the activity data, there was no main effect of PCP or VS and no interaction of 
both on the PCP reinstatement day (ps≥0.17). There was also no main effect of PCP or VS 
and no interaction on the PCP reinstatement day for inactive lever presses (ps≥0.21). 
Overall, rats that had either received PCP or a VS coupled to the nicotine infusion had 
higher active lever responding on the PCP reinstatement day than the saline and NO-VS 
groups. Data from the interaction shows that rats that were exposed to PCP and had a 
concurrent VS presentation reinstated more to the PCP trigger.
Nicotine Reinstatement—There was a main effect of VS on the nicotine reinstatement 
day [F(1,34)=15.987, p<0.001], with rats in the VS groups having higher active lever-
pressing than rats in the NO-VS groups. There was no main effect of PCP, although the 
effect was trending towards significance (p≥0.057). There was no interaction of PCP and VS 
on the nicotine reinstatement day (p≥0.16). Active lever-pressing did not differ between the 
final extinction day and the nicotine reinstatement test (p=0.59). Examining the activity data, 
there was a main effect of previous PCP exposure on nicotine reinstatement [F(1,34)=3.809, 
p=0.039], with higher levels of activity seen in the rats that had nicotine previously paired 
with PCP (509.7±41.3) than the saline groups (355.95±50.2), but there was no main effect 
of VS and no interaction of PCP and the VS on the nicotine reinstatement day. For inactive 
lever-pressing data, there was no main effect of VS and PCP and no interaction (ps≥0.28).
Yohimbine Reinstatement—There was a main effect of VS on yohimbine reinstatement 
day [F(1,34)=22.856, p<0.001], with rats in the VS groups having higher active lever-
pressing than the NO-VS groups. There was no main effect of PCP (p=0.079), yet there was 
an interaction of PCP and VS [F(1,34)=4.494, p=0.041]. Rats in the PCP-VS groups had 
higher lever pressing than the SAL-VS and both NOVS groups (LSDmmd=28.36). Active 
lever-pressing differed between the final extinction day and the yohimbine reinstatement test 
[F(1,34)=9.590, p=0.0038] and this effect was specific to the PCP-VS group (p<0.001) as no 
other groups showed increased responding on the PCP reinstatement day (ps>0.05). There 
were no main effects and no interaction on activity measures (ps≥0.44) or inactive lever-
pressing (ps≥0.41). This interaction indicates that rats that were exposed to phencyclidine 
and had a concurrent VS presentation reinstated to a pharmacological stressor; an effect not 
seen in any other group.
Discussion
We found that pretreatment with phencyclidine initially attenuated nicotine self-
administration but only in the groups with a paired visual stimulus. This attenuation 
dissipated after 5 days, shown by equivalent lever-pressing between the control and 
phencyclidine groups. Active lever responding in the VS groups dropped to NOVS levels 
upon removal of nicotine at the onset of the extinction phase indicating the import of the co-
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occurrence of nicotine with the VS for maintaining responding. After extinction, 
reinstatement tests revealed that rats in the PCP-VS group were more sensitive to 
phencyclidine- and yohimbine-induced reinstatement. These results point to two factors that 
may be involved in the comorbidity between nicotine abuse and aspects of schizophrenia: 
differential responsivity to the reward-enhancement effect of nicotine and an increased 
vulnerability to stress-induced reinstatement.
We found that phencyclidine, used to model the negative symptoms of schizophrenia, 
decreased nicotine self-administration. These results are dissimilar to those found by Berg 
and colleagues (2013), in which the neonatal ventral hippocampal lesion preclinical model 
increased nicotine self-administration. The two models each encapsulate unique aspects of 
certain components of schizophrenia. The neonatal ventral hippocampal lesion paradigm is 
better at modeling the developmental aspects of this disorder, whereas PCP more 
consistently produces symptoms resembling the positive and negative symptomology of 
schizophrenia, such as anhedonia and memory deficits (Tseng et al. 2008; Javitt & Zukin 
1991). The differential nature of the constructs that each model captures could be a potential 
factor in the disparate results.
In the present study, the attenuation of nicotine self-administration seems to be somewhat 
transient and is seen primarily on days 3 through 5 of nicotine self-administration before 
returning to saline levels. This finding is similar to those seen after repeated PCP injections 
in an intracranial self-stimulation (ICSS) and a conditioned place preference task (Amitai et 
al. 2009; Iwamoto, 1986; Kitaichi et al. 1996). In these tasks, phencyclidine initially 
produced a decrease in reward-related behavior, shown by increased reward thresholds in 
the ICSS task and an aversion to the chamber previously paired with phencyclidine in the 
place conditioning task. After repeated injections, this initial reward deficit was reversed, 
eventually attenuating reward thresholds and, in a separate study, leading to a conditioned 
place preference. Combined, these studies suggest that one potential mechanism behind the 
transient decrease in nicotine self-administration in the PCP-VS is tolerance to the initial 
decrease in reward seen after PCP exposure.
Tolerance to the reward-attenuating effects of phencyclidine might not be the only 
mechanism at play. NMDA receptor antagonists such as dizocilpine and D-CCPene 
decreased nicotine sensitization of the mesolimbic dopaminergic system (Shoaib et al. 
1994). Dextrorphan, which substitutes for phencyclidine in drug discrimination studies and 
antagonizes NMDA receptors, decreases selective nicotinic acetylcholine receptors 
(nAChRs), such as the α2β3 variety (Nicholson et al. 1999; Franklin & Murray 1992; Damaj 
et al. 2005; Wright et al. 2006). A competitive NMDA receptor antagonist (LY235959) 
acutely reduced nicotine self-administration and this finding was related to its actions in the 
central nucleus of the amygdala and ventral tegmental area (Kenny et al. 2009). In addition, 
phencyclidine is a noncompetitive inhibitor of nAChRs (Connolly et al. 1992; Fryer & 
Lukas 1999). A potential hypothesis for the initial decrease of nicotine self-administration is 
blockade by PCP of nAChRs. A progressive upregulation of nAChRs in response to the 
inhibition by PCP could lead to the dissipation of this attenuation seen on day 6.
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Another potential explanation of the self-administration findings is that the effects of 
phencyclidine might be specific to the reinforcement-enhancement effect of nicotine. Our 
findings first support the seminal study done by Caggiula and colleagues (2002) which 
suggests that the reinforcement of the visual stimulus concurrent with a nicotine infusion is 
enhanced by nicotine. We found that nicotine self-administration was enhanced by co-
administration of a visual stimulus. PCP administration reduced self-administration levels 
only in the VS-paired group but did not potentiate or attenuate lever-pressing in animals in 
the NOVS group. The attenuation in the VS-paired group was not due to a suppression of 
locomotion, as chamber activity was actually increased by PCP administration. The transient 
reduction could be due to the mechanisms discussed above, such as receptor blockade and 
potentially progressive upregulation of nAChRs. An alternative hypothesis is that nicotine 
self-administration in groups without a concurrent visual stimulus is low enough that further 
reductions might not be possible (i.e. a floor effect). While this is a valid theory in 
explaining the lack of the effect in the NOVS conditions, a floor effect explanation cannot 
explain the transient attenuation in the VS group.
The trend of phencyclidine interacting with only the visual stimulus-paired group extended 
into the reinstatement period as well. When rats were tested in a reinstatement procedure 
with PCP, only rats in group PCP-VS showed reinstatement. The low levels of nicotine self-
administration in the non-visual stimulus groups explain the lack of reinstatement behavior 
on all three reinstatement days while the reinstatement in the PCP-VS group could be seen 
as cue-induced. In a typical cue-induced reinstatement paradigm, rats are given a cue 
(typically a visual stimulus) previously coupled to the infusion and levels of drug-seeking 
behavior are examined. In this experiment, PCP was only given during the self-
administration days and neither PCP nor saline was given during extinction. Thus, the 
interoceptive stimulus effects of PCP could act as a cue or context for availability of 
nicotine. Not surprisingly, the PCP-NOVS group did not show enhanced active lever 
pressing during the PCP reinstatement test. Again, this notes the import of the conjoint 
presence of the visual stimulus and nicotine to the later effect of PCP.
Finally, the yohimbine reinstatement test showed that only rats previously exposed to 
phencyclidine with a concurrent visual stimulus increased active lever pressing. Yohimbine, 
an α2 adrenergic receptor antagonist, has been widely used as a pharmacological stressor as 
it induces an increase in stress-like behaviors in both human and non-human animals (Li et 
al. 2012; Stine et al. 2002; Davis et al. 1979; Charney et al. 1983). Yohimbine has been 
shown to increase drug-seeking behaviors in a reinstatement model for drugs such as 
methamphetamine, cocaine, and nicotine (Shepard et al. 2004; Lee et al. 2004; Feltenstein et 
al. 2012). Perhaps the interoceptive stimulus effects of yohimbine might be similar to the 
effects of phencyclidine and the reinstatement reflects this generalization between 
yohimbine and PCP. We could find no study to date that has examined whether 
phencyclidine and yohimbine substitute for one another in a drug discrimination task. 
Generalizability between the two substances, however, seems unlikely given the 
dissimilarity between mechanisms of actions. Phencyclidine works as an NMDA antagonist 
and yohimbine as an α2 adrenergic antagonist. Yohimbine also counteracts phencyclidine-
induced behaviors such as head bobbing and hyperlocomotion (Byron et al. 1985; Freed et 
al., 1980).
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There are two potential limitations of this study. First, reinstatement tests were not 
counterbalanced. This procedural decision reflects our primary interest in the PCP model of 
negative and cognitive symptoms seen in schizophrenia. By testing phencyclidine first, 
exactly one week after the last day of PCP exposure, our test of PCP reinstatement was 
unaffected by other reinstatement ligands. Of course, this decision means that interpretation 
of the nicotine and yohimbine outcomes should be interpreted with the lack of 
counterbalancing in mind. The second limitation is the lack of a saline control in 
reinstatement to assess the possibility the PCP sensitized rats in an manner that allowed an 
injection to simply reinstate active lever presses. Our data does not support this possibility. 
First, recall that PCP-NOVS also has similar treatment with PCP in the self-administration 
phase. Despite having similar PCP exposure as PCP-VS, they do not show any sign of 
increased responding across all reinstatement tests. Second, this sensitization account would 
not predict the pattern of reinstatement in the PCP-VS group. That is, reinstatement should 
be seen on all 3 tests, or only on the first test if the effect was transient. Instead, 
reinstatement was only seen on the first and third tests, suggesting that reinstatement effects 
were related to the pharmacological effects of the reinstatement ligand.
The present study revealed important interactions between nicotine, PCP and a 
pharmacological stressor. Future studies could be conducted to investigate other factors 
involved in this complex relationship. First, the length of the self-administration period was 
chosen based on its ability to consistently model many aspects of schizophrenia but it may 
not have been long enough to fully capture the effects of phencyclidine on nicotine self-
administration. Future work extending the length of self-administration and administering 
phencyclidine during both the maintenance and acquisition of self-administration is integral. 
Research utilizing an escalating fixed ratio or progressive ratio schedule could explicate 
behavioral mechanisms involved in this transient disruption of nicotine self-administration, 
especially using a procedure involving prior food training.
Stress has long been known to be an integral factor in the etiology of schizophrenia (Walker 
& Diforio 1997; Tennant 1985) and is also widely implicated in the development, 
continuation, and reemergence of drug addiction in both clinical and preclinical models 
(Tomkins 1966; Koob & Le Moal, 1997; see Sinha 2008 for review). Reinstatement by 
yohimbine of nicotine-seeking behavior suggests that a rat may be more sensitive to 
pharmacological stressors after being exposed to phencyclidine, used here to model the 
negative symptoms of schizophrenia. Future research to characterize this effect and 
determine whether this extends to other stressors is necessary. The specificity of these 
findings (e.g. that reinstatement and disruption of self-administration is only seen when 
nicotine is paired with a visual cue) implies that the nicotine reinstatement-enhancement 
effect might be particularly altered in a preclinical model of the negative symptoms of 
schizophrenia. Together, the self-administration and reinstatement evidence propose a role 
of the reinforcement-enhancement effect of nicotine in the comorbidity between tobacco use 
and schizophrenia.
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Figure 1. 
Number of nicotine infusions earned over the 60-min session for the seven days of self-
administration. Phencyclidine initially decreased self-administration of nicotine in the 
concurrent VSs condition but this rebounded to saline levels by day 6. * indicates p<0.05
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Figure 2. 
Discrimination index for the seven days of self-administration. Rats in the NOVS condition 
had a significantly lower discrimination index (indicated by *) than rats in the VS condition. 
PCP had no effect on discrimination index. The line at 0.5 indicates when active lever-
pressing equals inactive lever-pressing.
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Figure 3. 
Number of beam breaks over the seven days of self-administration. Activity was higher 
overall in the PCP condition in comparison to the SAL condition.* indicates a significant 
difference.
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Figure 4. 
Final day of self-administration followed by extinction and reinstatement data (all shown in 
number of active lever presses). Active lever presses includes lever-pressing during the 20-
second timeout. Rats in the VS conditions had higher active lever-pressing on all 
reinstatement days in comparison to the NOVS conditions (which showed no reinstatement 
behavior). * indicated that rats in the combined PCP/VS condition had potentiated active 
lever-pressing on the PCP and yohimbine reinstatement days in comparison to all other 
groups.
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